Literature DB >> 16260616

The basic domain of ATH5 mediates neuron-specific promoter activity during retina development.

Dorota Skowronska-Krawczyk1, Lidia Matter-Sadzinski, Marc Ballivet, Jean-Marc Matter.   

Abstract

In the developing retina, the gene encoding the beta3 subunit of the neuronal nicotinic receptor, a specific marker of retinal ganglion cells, is under the direct control of the atonal homolog 5 (ATH5) basic helix-loop-helix (bHLH) transcription factor. Although quite short (143 bp in length), the beta3 promoter has the remarkable capacity to discriminate between ATH5 and the other neuronal bHLH proteins expressed in the developing nervous system. We have identified three amino acids within the basic domain that confer specificity to the ATH5 protein. These residues do not mediate direct DNA binding but are required for interaction between ATH5 and chromatin-associated proteins during retina development. When misexpressed in neurons, the myogenic bHLH factor MyoD is also able to activate the beta3 gene. This, however, is achieved not by binding of the protein to the promoter but by dimerization of MyoD with a partner, a process that depends not on the basic domain but on the HLH domain. By sequestering an E-box-binding protein, MyoD relieves the active repression that blocks the beta3 promoter in most neurons. The mechanisms used by bHLH proteins to activate beta3 thus highlight how ATH5 is selected by the beta3 promoter and coordinates the derepression and transcriptional activation of the beta3 gene during the specification of retinal ganglion cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16260616      PMCID: PMC1280256          DOI: 10.1128/MCB.25.22.10029-10039.2005

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  37 in total

Review 1.  The role of basic helix-loop-helix genes in vertebrate retinogenesis.

Authors:  M L Vetter; N L Brown
Journal:  Semin Cell Dev Biol       Date:  2001-12       Impact factor: 7.727

Review 2.  Inhibitors of DNA binding in neural cell proliferation and differentiation.

Authors:  Shun-Fen Tzeng
Journal:  Neurochem Res       Date:  2003-01       Impact factor: 3.996

Review 3.  Proneural genes and the specification of neural cell types.

Authors:  Nicolas Bertrand; Diogo S Castro; François Guillemot
Journal:  Nat Rev Neurosci       Date:  2002-07       Impact factor: 34.870

4.  X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors.

Authors:  Satish K Nair; Stephen K Burley
Journal:  Cell       Date:  2003-01-24       Impact factor: 41.582

5.  Distinct domains within Mash1 and Math1 are required for function in neuronal differentiation versus neuronal cell-type specification.

Authors:  Yuji Nakada; Thomas L Hunsaker; R Michael Henke; Jane E Johnson
Journal:  Development       Date:  2004-03       Impact factor: 6.868

6.  The MyoD DNA binding domain contains a recognition code for muscle-specific gene activation.

Authors:  R L Davis; P F Cheng; A B Lassar; H Weintraub
Journal:  Cell       Date:  1990-03-09       Impact factor: 41.582

7.  A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins.

Authors:  C Murre; P S McCaw; D Baltimore
Journal:  Cell       Date:  1989-03-10       Impact factor: 41.582

8.  Evolution of neural precursor selection: functional divergence of proneural proteins.

Authors:  Xiao-Jiang Quan; Tinneke Denayer; Jiekun Yan; Hamed Jafar-Nejad; Anne Philippi; Olivier Lichtarge; Kris Vleminckx; Bassem A Hassan
Journal:  Development       Date:  2004-03-17       Impact factor: 6.868

9.  Highly specific interactions between bHLH transcription factors and chromatin during retina development.

Authors:  Dorota Skowronska-Krawczyk; Marc Ballivet; Brian D Dynlacht; Jean-Marc Matter
Journal:  Development       Date:  2004-09       Impact factor: 6.868

10.  Math3 and NeuroD regulate amacrine cell fate specification in the retina.

Authors:  Tomoyuki Inoue; Masato Hojo; Yasumasa Bessho; Yasuo Tano; Jacqueline E Lee; Ryoichiro Kageyama
Journal:  Development       Date:  2002-02       Impact factor: 6.868

View more
  6 in total

1.  Prosurvival long noncoding RNA PINCR regulates a subset of p53 targets in human colorectal cancer cells by binding to Matrin 3.

Authors:  Ritu Chaudhary; Berkley Gryder; Wendy S Woods; Murugan Subramanian; Matthew F Jones; Xiao Ling Li; Lisa M Jenkins; Svetlana A Shabalina; Min Mo; Mary Dasso; Yuan Yang; Lalage M Wakefield; Yuelin Zhu; Susan M Frier; Branden S Moriarity; Kannanganattu V Prasanth; Pablo Perez-Pinera; Ashish Lal
Journal:  Elife       Date:  2017-06-05       Impact factor: 8.140

2.  Biasing amacrine subtypes in the Atoh7 lineage through expression of Barhl2.

Authors:  Patricia R Jusuf; Shahad Albadri; Alessio Paolini; Peter D Currie; Francesco Argenton; Shin-ichi Higashijima; William A Harris; Lucia Poggi
Journal:  J Neurosci       Date:  2012-10-03       Impact factor: 6.167

Review 3.  Context dependence of proneural bHLH proteins.

Authors:  Lynn M Powell; Andrew P Jarman
Journal:  Curr Opin Genet Dev       Date:  2008-09-07       Impact factor: 5.578

4.  In vivo neuronal subtype-specific targets of Atoh1 (Math1) in dorsal spinal cord.

Authors:  Helen C Lai; Tiemo J Klisch; Rene Roberts; Huda Y Zoghbi; Jane E Johnson
Journal:  J Neurosci       Date:  2011-07-27       Impact factor: 6.167

5.  Functional Characterization of an In-Frame Deletion in the Basic Domain of the Retinal Transcription Factor ATOH7.

Authors:  David Atac; Lucas Mohn; Silke Feil; Kevin Maggi; Dominik Haenni; Britta Seebauer; Samuel Koller; Wolfgang Berger
Journal:  Int J Mol Sci       Date:  2022-01-19       Impact factor: 5.923

6.  Integrating computational biology and forward genetics in Drosophila.

Authors:  Stein Aerts; Sven Vilain; Shu Hu; Leon-Charles Tranchevent; Roland Barriot; Jiekun Yan; Yves Moreau; Bassem A Hassan; Xiao-Jiang Quan
Journal:  PLoS Genet       Date:  2009-01-23       Impact factor: 5.917

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.